Form 4: Centessa Pharmaceuticals Acquisition Complete

Centessa Pharmaceuticals plc's acquisition by Eli Lilly and Company has been finalized, with shareholders receiving cash and contingent value rights.

Summary

• Centessa Pharmaceuticals plc has been acquired by Eli Lilly and Company through a scheme of arrangement.
• The transaction, effective June 24, 2026, involved Eli Lilly's subsidiary LDH XV Corporation acquiring all outstanding ordinary shares.
• Shareholders are entitled to receive $38.00 in cash per ordinary share, plus a non-transferable contingent value right (CVR) for potential additional payments up to $9.00 per share.
• These CVR payments are contingent upon the achievement of specified milestones.
• All outstanding share options and restricted share units (RSUs) were cancelled and converted into the right to receive cash and CVRs.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this as a highly positive development for Centessa shareholders, reflecting a successful acquisition at a substantial valuation with potential for further upside.

Positives

• Shareholders will receive a cash payment of $38.00 per share, representing a significant return.
• The potential for up to an additional $9.00 per share through CVRs offers upside potential based on future milestones.
• The acquisition by a major pharmaceutical company like Eli Lilly and Company provides a strong exit for investors.

Negatives

• The CVR payments are contingent and not guaranteed, meaning the full potential value may not be realized.
• Ordinary shares will no longer be publicly traded, limiting future liquidity for shareholders.

Risks

• The realization of contingent value rights (CVRs) is dependent on the achievement of specified milestones, which may not occur.
• Potential withholding taxes may reduce the net cash consideration received by shareholders.

Future Outlook

The future outlook for Centessa Pharmaceuticals plc is now integrated within Eli Lilly and Company. The contingent value rights (CVRs) provide a mechanism for former Centessa shareholders to benefit from the achievement of specific future milestones, indicating a forward-looking component tied to the company's pipeline or development progress.

Management Comments

• The transfer of Ordinary Shares occurred automatically at the Effective Time pursuant to the Scheme of Arrangement, without any action by or discretion of the Reporting Person.
• At the effective time of the Scheme of Arrangement (the 'Effective Time'), holders of Ordinary Shares became entitled to receive (a) $38.00 in cash per Ordinary Share (the 'Cash Consideration'), without interest and less any applicable withholding taxes, and (b) one non-transferable contingent value right (a 'CVR') entitling the holders to receive contingent payments of up to an aggregate of $9.00 per Ordinary Share, without interest and less any applicable withholding taxes, contingent upon the achievement of specified milestones set forth in the Contingent Value Rights Agreement between Parent, Purchaser and a rights agent mutually agreeable to the Company and Parent.

Industry Context

StockSavvy.ai notes that this acquisition by Eli Lilly and Company is consistent with broader industry trends of consolidation, where larger pharmaceutical companies acquire innovative smaller biotechs to bolster their pipelines, particularly in areas with high unmet medical needs.

Comparison to Industry Standards

• The acquisition price of $38.00 per share plus potential CVRs of up to $9.00 per share represents a significant premium, often seen in strategic acquisitions of clinical-stage or early-commercial biopharmaceutical companies.
• The structure involving cash and contingent value rights is a common mechanism in M&A deals within the pharmaceutical sector, allowing acquirers to mitigate risk while offering sellers potential upside based on future success, as seen in numerous deals involving companies like Pfizer, Merck, and Bristol Myers Squibb.

Stakeholder Impact

• Shareholders: Receive $38.00 cash per share plus potential CVRs, representing a significant return on investment.
• Employees: Potential for integration into Eli Lilly and Company, with implications for roles and employment terms.
• Creditors: The acquisition by Eli Lilly and Company, a financially strong entity, likely ensures continued fulfillment of Centessa's obligations.

Next Steps

• Shareholders to receive $38.00 in cash per ordinary share.
• Shareholders to receive one non-transferable contingent value right (CVR) per ordinary share, with potential for up to $9.00 per share based on milestones.
• Integration of Centessa Pharmaceuticals plc's assets and pipeline into Eli Lilly and Company.

Key Dates

Recommendation

For existing shareholders, the transaction represents a successful exit with a cash payout and potential upside via CVRs. The recommendation is to hold and await the realization of CVRs, as the immediate cash component provides a solid floor. For new investors, the opportunity to acquire shares at the pre-acquisition market price is gone, and the focus shifts to the value of the CVRs and Eli Lilly's integration strategy.

Keywords

Centessa Pharmaceuticals, Eli Lilly and Company, Acquisition, Scheme of Arrangement, Form 4, SEC Filing, Shareholder Value, Contingent Value Rights, Ordinary Shares, Stock Options, RSUs